(2.2)
(C43.4)
= Dr Smit
AbbVie Inc. (AbbVie)
Colorectal Cancer
Core Risk Management Plan
Core Risk Management Plan for
DOSAGE AND ADMINISTRATION
Data lock point forthis RMP: 31 December 2021
Date of final sign off: September 2024
Dx: metustatc melanoma
Esophageal Cancer
Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
Hepatocellular Carcinoma (HCC)
Humira
INDICATIONS AND USAGE
IV g3uks
Information.
KEYTRUDA is also indicated for
Pt: Jane Doe
RMP Annex 8.
RMP Version Number: 16.2
RMP version to be assessed as part of this application:
Rationale for submitting an updated RMP:
Reclassified Missing Information "Episodic treatment in Ps, UC and JIA" to "Episodic treatment
Removed Long Term Safety Information in the Treatment of Children with Uveitis from Missing
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Start Keytruda 200 me.
Summary of significant changes in the RMP: A summary of significant changes is included in
This indication is approved under accelerated approval based on overall response rate and duration of
Urothelial Carcinoma
Version 16.2 / Data Lock Point 31 December 2021
[OCR skipped on page(s) 1]
a
after undergoing radical resection of UC. (1.10)
aobbvie Adalimumab
carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13)
clinical benefit in confirmatory trials.
combination with cisplatin and gemcitabine. (1.10)
disease progression on or after a platinum-based therapy. (1.9)
esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidineand platinum-containing chemotherapy. (1.14)
first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy
first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13)
in UC"
indication. (2)
instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination
lymphoma (cHL) that has relapsed
mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following
on the same day every 3 weeks for 4 doses, then 240 mg every 2 weeks or 480 mg every 4
or progressed after three or more
pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13)
patients with classical Hodgkin
previously treated with sorafenib. (1.12)
prior lines of therapy.
response. Continued approval for this indication may be contingent upon verification and description of
the treatment of adult and pediatric
treatment in combination with ipilimumab. (1.12)
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.11)
weeks. (2.2)
whose tumors express PD-L1 (≥1). (1.13)
with ipilimumab. (1.11)
• Administer by intravenous infusion after dilution based upon recommended infusion rate for each
• Adult and pediatric patients weighing 40 kg or greater: 1 mg/kg followed by ipilimumab 3 mg/kg
• Adult and pediatric patients weighing 40 kg or greater: 240 mg every 2 weeks or 480 mg every 4
• Pediatric patients weighing less than 40 kg: 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks.
• Unresectable or metastatic melanoma
• adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence
• adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or
• adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite
• adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and
• adult patients with completely resected esophageal or gastroesophageal junction cancer with residual
• adult patients with locally advanced or metastatic urothelial carcinoma who:
• adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with
• adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as
• adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell
• adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line
• adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in
• have disease progression during or following platinum-containing chemotherapy.
• have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy. (1.10)
• in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been